Symbols / ZURA Stock $5.38 -2.54% Zura Bio Limited

Healthcare • Biotechnology • United States • NCM
ZURA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Sandeep C. Kulkarni M.D.
Exch · Country NCM · United States
Market Cap 510.46M
Enterprise Value 401.05M
Income -99.35M
Sales —
FCF (ttm) -42.52M
Book/sh 1.38
Cash/sh 1.15
Employees 40
Insider 10d —
IPO Mar 21, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -53.80
PEG —
P/S —
P/B 3.90
P/C —
EV/EBITDA -5.33
EV/Sales —
Quick Ratio 8.82
Current Ratio 9.05
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.06
EPS next Y -0.10
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-19
ROA -32.05%
ROE -52.49%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 94.88M
Shs Float 54.74M
Insider Own 21.12%
Instit Own 56.45%
Short Float 6.93%
Short Ratio 9.75
Short Interest 6.15M
52W High 7.44
vs 52W High -27.69%
52W Low 0.98
vs 52W Low 448.98%
Beta 0.24
Impl. Vol. 38.23%
Rel Volume 1.15
Avg Volume 560.64K
Volume 642.68K
Target (mean) $15.50
Tgt Median $15.00
Tgt Low $11.00
Tgt High $26.00
# Analysts 6
Recom None
Prev Close $5.52
Price $5.38
Change -2.54%
About

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.50
Mean price target
2. Current target
$5.38
Latest analyst target
3. DCF / Fair value
$-8.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.38
Low
$11.00
High
$26.00
Mean
$15.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-23 main Chardan Capital Buy → Buy $11
2026-03-20 main Oppenheimer Outperform → Outperform $15
2026-02-09 init Wedbush — → Outperform $15
2025-11-14 main Chardan Capital Buy → Buy $10
2025-11-13 init Clear Street — → Buy $18
2025-09-30 main Chardan Capital Buy → Buy $10
2025-08-19 main HC Wainwright & Co. Neutral → Neutral $2
2025-08-15 main Oppenheimer Outperform → Outperform $16
2025-08-15 main Chardan Capital Buy → Buy $10
2025-05-09 main Oppenheimer Outperform → Outperform $17
2025-04-03 main HC Wainwright & Co. Neutral → Neutral $3
2025-03-26 main Oppenheimer Outperform → Outperform $19
2025-03-26 reit Guggenheim Buy → Buy $15
2025-03-26 main Chardan Capital Buy → Buy $10
2024-12-24 reit HC Wainwright & Co. Neutral → Neutral $5
2024-12-11 reit Cantor Fitzgerald Overweight → Overweight —
2024-11-18 reit HC Wainwright & Co. Neutral → Neutral $5
2024-11-11 reit HC Wainwright & Co. Neutral → Neutral $5
2024-11-09 main Chardan Capital Buy → Buy $12
2024-11-04 init Leerink Partners — → Outperform $15
News
RSS: Latest ZURA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-26 AI BIOTECHNOLOGY L.L.C. Beneficial Owner of more than 10% of a Class of Security — 2,000,000 $6.25 $12,500,000
2024-11-25 THIARA PARVINDER Director — 1,001,633 $2.73 $2,734,458
2024-09-16 DAVIS KIMBERLY ANN Officer — 1,500 $0.00 $0
2024-09-11 THIARA PARVINDER Director — 3,800,000 $3.50 $13,300,000
2024-09-04 SIDHU SOMEIT Director — 51,728 $3.87 $200,187
2024-08-23 SIDHU SOMEIT Director — 1,557,081 $0.00 $0
2024-08-23 BADIAL VERENDER S Chief Financial Officer — 126,155 $0.00 $0
2024-05-17 PLOOS VAN AMSTEL ARNOUT Director — 80,000 $6.20 $496,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
75.25
+36.34%
55.19
-11.89%
62.64
+130.61%
27.16
Research And Development
42.08
+72.46%
24.40
-44.54%
44.00
+85.74%
23.69
Selling General And Administration
33.16
+7.72%
30.79
+65.18%
18.64
+436.68%
3.47
General And Administrative Expense
33.16
+7.72%
30.79
+65.18%
18.64
+436.68%
3.47
Other Gand A
33.16
+7.72%
30.79
+65.18%
18.64
+436.68%
3.47
Total Expenses
75.25
+36.34%
55.19
-11.89%
62.64
+130.61%
27.16
Operating Income
-75.25
-36.34%
-55.19
+11.89%
-62.64
-130.61%
-27.16
Total Operating Income As Reported
-75.25
-36.34%
-55.19
+11.89%
-62.64
-130.61%
-27.16
EBITDA
-75.20
-36.28%
-55.18
+11.91%
-62.64
-130.61%
-27.16
Normalized EBITDA
-75.20
-50.57%
-49.94
+22.88%
-64.75
-138.40%
-27.16
Reconciled Depreciation
0.05
+444.44%
0.01
0.00
—
EBIT
-75.25
-36.34%
-55.19
+11.89%
-62.64
-130.61%
-27.16
Total Unusual Items
—
-5.24
-347.64%
2.12
-66.00%
6.22
Total Unusual Items Excluding Goodwill
—
-5.24
-347.64%
2.12
-66.00%
6.22
Net Income
-68.65
-31.00%
-52.40
+13.18%
-60.36
-134.52%
-25.74
Pretax Income
-68.65
-31.00%
-52.40
+13.47%
-60.56
-121.57%
-27.33
Net Non Operating Interest Income Expense
6.34
-20.78%
8.00
+265.87%
2.19
+27225.00%
0.01
Net Interest Income
6.34
-20.78%
8.00
+265.87%
2.19
+27225.00%
0.01
Interest Income Non Operating
6.34
-20.78%
8.00
+265.87%
2.19
+27225.00%
0.01
Interest Income
6.34
-20.78%
8.00
+265.87%
2.19
+27225.00%
0.01
Other Income Expense
0.26
+104.99%
-5.21
-4595.50%
-0.11
+37.99%
-0.18
Other Non Operating Income Expenses
0.26
+828.57%
0.03
+101.26%
-2.23
-1144.13%
-0.18
Gain On Sale Of Security
—
-5.24
-347.64%
2.12
-66.00%
6.22
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-68.65
-31.00%
-52.40
+13.47%
-60.56
-121.57%
-27.33
Net Income From Continuing Operation Net Minority Interest
-68.65
-31.00%
-52.40
+13.18%
-60.36
-134.52%
-25.74
Net Income From Continuing And Discontinued Operation
-68.65
-31.00%
-52.40
+13.18%
-60.36
-134.52%
-25.74
Net Income Continuous Operations
-68.65
-31.00%
-52.40
+13.47%
-60.56
-121.57%
-27.33
Minority Interests
—
0.00
-100.00%
0.20
-87.27%
1.59
Normalized Income
-68.65
-45.56%
-47.16
+24.51%
-62.48
-142.74%
-25.74
Net Income Common Stockholders
-99.35
-118.91%
-45.39
+34.45%
-69.24
-113.78%
-32.39
Otherunder Preferred Stock Dividend
30.70
+537.55%
-7.02
-178.99%
8.88
+33.54%
6.65
Diluted EPS
-1.06
-76.67%
-0.60
+71.29%
-2.09
+82.86%
-12.19
Basic EPS
-1.06
-76.67%
-0.60
+71.29%
-2.09
+82.86%
-12.19
Basic Average Shares
94.16
+25.43%
75.07
+127.05%
33.06
+1466.27%
2.11
Diluted Average Shares
94.16
+25.43%
75.07
+127.05%
33.06
+1466.27%
2.11
Diluted NI Availto Com Stockholders
-99.35
-118.91%
-45.39
+34.45%
-69.24
-113.78%
-32.39
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
113.95
-36.53%
179.53
+78.03%
100.84
+1816.44%
5.26
Current Assets
112.31
-37.17%
178.74
+77.25%
100.84
+5578.10%
1.78
Cash Cash Equivalents And Short Term Investments
109.41
-38.01%
176.50
+76.84%
99.81
+6269.24%
1.57
Cash And Cash Equivalents
109.41
-38.01%
176.50
+76.84%
99.81
+6269.24%
1.57
Cash Equivalents
—
—
97.91
—
Cash Financial
—
—
1.89
+13632.32%
0.01
Prepaid Assets
—
—
—
0.02
Other Current Assets
2.90
+29.25%
2.25
+116.59%
1.04
+396.17%
0.21
Total Non Current Assets
1.64
+107.60%
0.79
0.00
-100.00%
3.49
Net PPE
0.13
+38.46%
0.09
0.00
—
Non Current Deferred Assets
—
—
0.00
-100.00%
3.49
Other Non Current Assets
1.51
+116.62%
0.70
—
141.47
Total Liabilities Net Minority Interest
12.41
-36.40%
19.51
-8.35%
21.29
-22.06%
27.32
Current Liabilities
12.41
-36.40%
19.51
-3.88%
20.30
+37.01%
14.82
Payables And Accrued Expenses
9.09
-48.93%
17.80
-6.81%
19.10
+345.56%
4.29
Payables
1.28
+74.49%
0.73
-73.34%
2.75
+36.77%
2.01
Accounts Payable
1.28
+74.49%
0.73
-73.34%
2.75
+36.77%
2.01
Current Accrued Expenses
7.81
-54.23%
17.07
+4.38%
16.35
+618.14%
2.28
Pensionand Other Post Retirement Benefit Plans Current
3.32
+93.75%
1.71
+42.63%
1.20
+751.77%
0.14
Current Debt And Capital Lease Obligation
—
—
—
7.76
Current Debt
—
—
—
7.76
Other Current Liabilities
—
—
—
2.63
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
0.99
-92.08%
12.50
Non Current Deferred Liabilities
—
—
—
4.01
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
12.50
Stockholders Equity
101.54
-30.84%
146.81
+147.45%
59.33
+285.08%
-32.06
Common Stock Equity
101.54
-30.84%
146.81
+147.45%
59.33
+285.08%
-32.06
Capital Stock
0.01
+0.00%
0.01
+75.00%
0.00
0.00
Common Stock
0.01
+0.00%
0.01
+75.00%
0.00
0.00
Preferred Stock
—
0.00
0.00
0.00
Share Issued
73.68
+12.84%
65.30
+49.79%
43.59
+61.15%
27.05
Ordinary Shares Number
73.68
+12.84%
65.30
+49.79%
43.59
+61.15%
27.05
Additional Paid In Capital
326.08
+7.72%
302.70
+85.91%
162.82
0.00
Retained Earnings
-224.55
-44.04%
-155.90
-50.63%
-103.49
-222.85%
-32.06
Minority Interest
0.00
-100.00%
13.20
-34.70%
20.22
+102.21%
10.00
Total Equity Gross Minority Interest
101.54
-36.55%
160.02
+101.15%
79.55
+460.68%
-22.06
Total Capitalization
101.54
-30.84%
146.81
+147.45%
59.33
+285.08%
-32.06
Working Capital
99.90
-37.26%
159.23
+97.70%
80.54
+717.55%
-13.04
Invested Capital
101.54
-30.84%
146.81
+147.45%
59.33
+344.16%
-24.30
Total Debt
—
—
—
7.76
Net Debt
—
—
—
6.19
Net Tangible Assets
101.54
-30.84%
146.81
+147.45%
59.33
+285.08%
-32.06
Tangible Book Value
101.54
-30.84%
146.81
+147.45%
59.33
+285.08%
-32.06
Current Notes Payable
—
—
0.00
-100.00%
7.76
Derivative Product Liabilities
—
0.00
-100.00%
0.99
0.00
Dueto Related Parties Current
—
—
—
0.08
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-64.81
-130.86%
-28.08
-86.50%
-15.05
-1152.41%
-1.20
Cash Flow From Continuing Operating Activities
-64.81
-130.86%
-28.08
-86.50%
-15.05
-1152.41%
-1.20
Net Income From Continuing Operations
-68.65
-31.00%
-52.40
+13.47%
-60.56
-121.57%
-27.33
Depreciation Amortization Depletion
0.05
+444.44%
0.01
0.00
—
Depreciation And Amortization
0.05
+444.44%
0.01
0.00
—
Other Non Cash Items
0.00
—
29.23
+32.42%
22.08
Stock Based Compensation
12.33
-26.59%
16.80
+73.98%
9.65
+2790.72%
0.33
Operating Gains Losses
-4.92
-194.30%
5.21
+803.51%
-0.74
-3321.74%
0.02
Gain Loss On Investment Securities
—
5.24
+823.76%
-0.72
+88.37%
-6.22
Unrealized Gain Loss On Investment Securities
—
0.00
-100.00%
2.24
+1338.46%
0.16
Net Foreign Currency Exchange Gain Loss
0.08
+411.11%
-0.03
-58.82%
-0.02
-173.91%
0.02
Change In Working Capital
-3.63
-257.52%
2.31
-54.91%
5.12
+44.48%
3.54
Change In Receivables
—
—
—
0.00
Change In Prepaid Assets
-0.66
+45.66%
-1.21
-46.01%
-0.83
-296.17%
-0.21
Change In Payables And Accrued Expense
-2.16
-151.33%
4.21
-29.10%
5.94
+58.51%
3.75
Change In Accrued Expense
—
—
—
0.91
Change In Payable
—
—
—
0.29
Change In Account Payable
—
—
—
0.29
Change In Other Current Assets
-0.81
-16.62%
-0.70
0.00
—
Investing Cash Flow
-0.11
+97.77%
-5.08
+36.56%
-8.00
+33.33%
-12.00
Cash Flow From Continuing Investing Activities
-0.11
+97.77%
-5.08
+36.56%
-8.00
+33.33%
-12.00
Net PPE Purchase And Sale
-0.11
-50.67%
-0.07
0.00
—
Purchase Of PPE
-0.11
-50.67%
-0.07
0.00
—
Capital Expenditure
-0.11
+97.77%
-5.08
+36.56%
-8.00
+33.33%
-12.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-5.00
+37.50%
-8.00
+33.33%
-12.00
Purchase Of Intangibles
0.00
+100.00%
-5.00
+37.50%
-8.00
+33.33%
-12.00
Financing Cash Flow
-2.16
-101.97%
109.84
-9.44%
121.29
+721.27%
14.77
Cash Flow From Continuing Financing Activities
-2.16
-101.97%
109.84
-9.44%
121.29
+721.27%
14.77
Net Issuance Payments Of Debt
—
0.00
+100.00%
-10.00
-231.58%
7.60
Issuance Of Debt
—
—
0.00
-100.00%
7.60
Repayment Of Debt
—
0.00
+100.00%
-10.00
0.00
Long Term Debt Payments
—
—
-10.00
0.00
Net Long Term Debt Issuance
—
—
-10.00
0.00
Short Term Debt Issuance
—
—
0.00
-100.00%
7.60
Short Term Debt Payments
—
0.00
+100.00%
-10.00
0.00
Net Short Term Debt Issuance
—
0.00
+100.00%
-10.00
-231.58%
7.60
Net Common Stock Issuance
5.10
-91.61%
60.76
-47.81%
116.41
0.00
Proceeds From Stock Option Exercised
0.11
-99.79%
50.03
+211.33%
16.07
0.00
Net Other Financing Charges
-7.37
-680.30%
-0.94
+20.27%
-1.18
+58.18%
-2.83
Changes In Cash
-67.09
-187.48%
76.69
-21.93%
98.24
+6169.24%
1.57
Beginning Cash Position
176.50
+76.84%
99.81
+6269.24%
1.57
0.00
End Cash Position
109.41
-38.01%
176.50
+76.84%
99.81
+6269.24%
1.57
Free Cash Flow
-64.93
-95.86%
-33.15
-43.80%
-23.05
-74.63%
-13.20
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
5.10
-91.61%
60.76
-47.81%
116.41
0.00
Issuance Of Capital Stock
5.10
-91.61%
60.76
-47.81%
116.41
+1064.07%
10.00
Net Preferred Stock Issuance
—
—
0.00
-100.00%
10.00
Preferred Stock Issuance
—
—
0.00
-100.00%
10.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category